The West Midlands Has England’s Largest Pool of Overlooked Grant-Backed Businesses
NatWest’s *From Innovation to Impact* analysis, published on 14 September, gives the West Midlands a useful but uncomfortable distinction. The region has England’s largest share of grant-backed businesses still trading without a recorded follow-on equity round, exit or recognised scale-up signal.
That cohort accounts for 47.4% of the region’s grant-backed firms, against a UK average of 38.1%. Just 15.4% have secured follow-on equity investment, well below the national figure of 26.4%.
The data should not be read as a verdict on the quality of Midlands innovation. Nor is it a complete measure of commercial success: NatWest and Beauhurst classify businesses through observable corporate outcomes, using registered addresses. A company can be building revenues, technical capability or valuable partnerships without yet tripping one of those markers.
But the gap is meaningful. It points to a regional challenge that is less about generating ideas than turning technical promise into market proof.
Innovation needs a buyer as well as a backer
The West Midlands has established assets: strong engineering and advanced-manufacturing clusters, major universities, health and clean-tech capability, and a substantial base of innovative firms. NatWest identifies 1,743 innovative businesses in the region, including 838 recipients of public innovation grants.
Grant funding can de-risk exploration. It can support a prototype, clinical validation or early technical team. Yet the next stage asks different questions: which customer has a pressing enough problem to change its buying behaviour; how will the product fit an existing procurement process; what evidence will a cautious buyer need; and can the company deliver reliably at commercial scale?
A breakthrough becomes a business only when someone can make a defensible decision to buy it.
This is why commercialisation cannot be reduced to an equity-finance problem. Patient capital matters, especially for science-led ventures with long development cycles. But capital works best alongside customer discovery, sector-specific sales expertise, regulatory navigation, reference customers and corporate partners prepared to run meaningful trials.
Birmingham’s opportunity is to connect the middle
The region has begun to build more of this infrastructure. Midlands Mindforge combines investment with company-building support for university spinouts, while the West Midlands Investment Zone explicitly positions the fund as a way to address regional equity gaps and attract private co-investment.
The recent backing for University of Birmingham spinout Healome Therapeutics illustrates the logic. Its eye-drop matrix technology has a clear translational route, but its progress depends on much more than laboratory performance: pre-clinical development, regulatory engagement, manufacturing scale-up and eventual adoption in clinical settings. The company’s £2m funding round is useful precisely because it supports those steps rather than treating incorporation as an endpoint.
For Birmingham’s business community, this suggests a more practical role than simply celebrating local innovation. Larger manufacturers, professional-services firms, hospitals and public bodies can become demand-side partners: defining operational problems, offering credible test environments and, where appropriate, becoming early customers.
That is also an insight discipline. Spinouts need robust evidence on user needs, purchasing journeys, decision-makers, switching costs and the commercial language their buyers use. Too often, market understanding arrives after technical development has already narrowed the available choices.
Measure the route to market, not just the round
The regional response should therefore track more than money raised. Metrics such as paid pilots converted to contracts, time from demonstration to procurement, repeat revenue, customer concentration and the local retention of skilled teams would reveal whether the system is genuinely improving.
NatWest’s report identifies an opportunity, not an inevitability. Birmingham and the wider West Midlands do not need a larger inventory of promising projects. They need more ventures that can show, early and convincingly, why a specific customer should choose them now.
That is where a region known for making things can gain an advantage: joining research strength to a closer understanding of the markets that will ultimately decide its value.
Comments